(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 October 2012 (26.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/143477 A3

(51) International Patent Classification:
*C07K 14/705* (2006.01) *A61K 38/17* (2006.01)
*C12N 15/62* (2006.01) *A61P 35/00* (2006.01)
*C12N 15/12* (2006.01)

(21) International Application Number:
PCT/EP2012/057219

(22) International Filing Date:
19 April 2012 (19.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PL394618 19 April 2011 (19.04.2011) PL

(71) Applicant *(for all designated States except US)*: **ADAMED SP. Z O.O.** [PL/PL]; Pieńków 149, PL-05-152 Czosnów k//Warszawy (PL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PIECZYKOLAN, Jerzy Szczepan** [PL/PL]; Gorajec - Zastawie 47, PL-22-463 Radecznica (PL). **PAWLAK, Sebastian Dominik** [PL/PL]; ul Majakowskiego 3/2, PL-01-420 Warszawa (PL). **ŻEREK, Bartłomiej Maciej** [PL/PL]; ul. Południowa 45/4, PL-97-200 Dąbrowa (PL). **RÓZGA, Piotr Kamil** [PL/PL]; ul. Bolesława Prusa 6/18, PL-96-100 Skierniewice (PL). **SZAWŁOWSKA, Urszula Marta** [PL/PL]; ul. Klaudyny 16 m.8, PL-01-684 Warszawa (PL).

(74) Agent: **SITKOWSKA, Jadwiga**; Al. Komisji Edukacji Narodowej 83/106, PL-02-777 Warszawa (PL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
14 March 2013

WO 2012/143477 A3

(54) Title: ANTICANCER FUSION PROTEIN

(57) Abstract: A fusion protein comprising domain (a) which is the functional fragment of a hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and at least one domain (b) which is the sequence of an effector peptide having anti-proliferative activity against tumour cells, wherein the sequence of domain (b) is attached at the C-terminus or at the N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.